Less stimulating

Results of a Phase II trial of Virus Research Institute Inc.'s Adjumer formulation of influenza vaccine illustrated one of the vagaries of clinical development of products such as flu vaccines, which depend on stimulating an immune response.

VRII (Cambridge, Mass.) and partner Pasteur-Merieux Connaught (Lyon, France) reported that the degree of improvement in immune response seen in the Phase II study was less than seen in a Phase I trial, while the control group in the new study did better than in the earlier trial...